DocGo Inc. (DCGO) Earnings Call Transcript & Summary
May 11, 2026
Earnings Call Speaker Segments
Mike Cole
executiveThanks, operator. Before we turn things over to management, there are a few points I'd like to address concerning forward-looking statements. Anything discussed on this conference call that does not constitute a statement of historical fact qualifies as a forward-looking statement. Words like may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, and project, plus similar phrases, may be used to identify these forward-looking statements. These forward-looking statements don't promise future performance, and we cannot guarantee that our plans, intentions, outcomes, results or expectations will be achieved or realized. Forward-looking statements carry significant risks, uncertainties, and assumptions by their very nature—many outside our control—and these could cause our actual results or outcomes, or the timing of when results or outcomes occur, to differ materially from what such statements imply. Some of these risks, uncertainties, and assumptions are discussed in the risk factors and other sections of DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, our earnings release for this quarter, and other filings and statements DocGo has submitted to the SEC, and we point you to those materials, though this list isn't exhaustive. Actual events and what we accomplish, or when those results or outcomes take place, might diverge materially from what these forward-looking statements express or imply. This call will also reference certain non-GAAP financial metrics. Reconciliations between those non-GAAP figures and the nearest comparable GAAP figures are available in our earnings release, as well as the Form 8-K current report containing that release, which is posted on docgo.com and has also been filed with the SEC. What we say on this call is accurate only as of the date being discussed, which is May 11, 2026. Investors should not assume that any statements will continue to apply or remain valid later on. We won't commit to updating anything covered on this call due to later developments, new information, or unforeseen events, unless the law requires us to. With that said, I'm glad to turn things over now to DocGo's CEO, Mr. Lee Bienstock. Go ahead, Lee.
Lee Bienstock
executiveThanks, Mike, and I appreciate everyone being here today. In the first quarter, we posted solid revenue at the top line, coming in at $75.6 million, together with an adjusted EBITDA loss of $10.2 million. On top of that, we raised our 2026 revenue guidance, moving it up from the $290 million to $310 million range to somewhere between $300 million and $315 million, and we kept our 2026 adjusted EBITDA guidance the same, still a loss of $5 million to $10 million. Let me spend a few minutes walking through revenue and profitability one at a time. To start, a big contributor to both our robust revenue results and our higher revenue guidance is SteadyMD, our virtual care offering. We flagged this upward trend on our prior earnings call, and we're happy to say it has picked up speed. In Q1, SteadyMD brought in more than $9 million in revenue, surpassing the prior record from last year's fourth quarter by about $1 million, and it handled roughly 1.1 million combined visits and lab orders in that stretch, a 38% rise versus a year ago. SteadyMD just signed a new agreement with a prominent online pharmacy to deliver virtual care for weight loss prescriptions along with a wide range of general clinical services, and that will drive further growth. Next, our mobile phlebotomy business is doing extremely well. Even though its revenue base is smaller, we now expect growth of up to 75% for this business in 2026, far ahead of what we previously anticipated, and we expect our pace of home visits to climb from 600 each day at present to 900 each day by the close of 2026; we've launched new territories across Upstate New York and Pennsylvania to keep up with demand for our services, and we intend to begin offering services in Florida, a state that's new for us. We're also broadening our technology use, collaborating with a large national lab to fold our order intake into their applications so physicians can request home visits straight through the lab systems, and putting AI automation to work for order intake and customer service to help lift our margins; and third, we've executed recent new contracts and expansions with payers and providers covering our care gap closure, PCP and transition of care services; we've now passed 1.6 million lives assigned to us for care gap services since we started, and visits completed are up 46% year-over-year. One more thing worth noting: we've started onboarding at an aggressive pace for PCP and longitudinal care services, and our panel now exceeds 1,000 patients, with the overwhelming majority of them enrolled during Q1. It's our goal for this business line to reach break-even in late 2026, which sharply reduces the investment level needed to launch and grow this business across the past few years. On the medical transportation side, we've closed several important renewals lately, along with a handful of smaller wins, which makes the long-term revenue picture for that segment even more solid. With one major New York hospital system, we extended our contract by another year, and with a second major New York health system, we renewed for 2 more years while bringing their Staten Island facilities into the fold. We also signed an agreement to serve a long-term acute care hospital located in Chattanooga, Tennessee, entered into contracts for medical transportation with a number of hospice facilities across Wisconsin, and secured a new contract for nonemergency patient transport services with the Great Western Hospitals NHS Foundation Trust in the United Kingdom. Beyond whatever is already baked into our updated revenue guidance, our business development pipeline is still robust and supports continued growth, with numerous opportunities to expand medical transportation, both within the U.S. and particularly in our U.K. operations. True to how we've always operated, we'll revise guidance as appropriate once contracts are actually signed. Taken together, we couldn't be happier about the near-term revenue growth potential across our consolidated business. At this point I want to change direction and walk through the gross margin and SG&A lines, so you can understand the thinking behind raising our revenue expectations while leaving adjusted EBITDA guidance where it was. Labor inefficiencies arose because of SteadyMD's outstanding growth. As I noted earlier, our expectations for this business in 2026 were high, and those ambitious expectations are now being surpassed. Such dramatic growth meant we had to pay bigger incentives to existing clinicians so shifts would be covered, while we worked to close a hiring gap. That wound up hurting our consolidated gross margin by roughly 60 basis points. In the first quarter, we put DocGo's recruiting know-how to work and grew SteadyMD's clinical workforce by more than 45%, and we anticipate that this larger workforce will help satisfy pent-up demand for SteadyMD services during the second half of the year. On top of that, fuel costs rose sharply in March because of the war in the Middle East, and we figure that each $1 increase at the pump translates into about 35 basis points of pressure on consolidated gross margin. What we paid on average in March was $3.69, versus an average cost of $2.93 per gallon across January and February. So far in Q2, average fuel costs have stayed at that elevated level, and we expect them to keep weighing on gross margin in the near term, which is different from the temporary squeeze on SteadyMD's margins I just mentioned, since that one has already righted itself during the second quarter so far. Finally, when operating expenses are adjusted to strip out depreciation, stock-based compensation and other nonrecurring items, we went from $35.7 million in last year's fourth quarter down to $34.1 million in this year's first quarter. In our view, that gives the clearest picture of how our cost-cutting efforts are flowing through our financials. This process clearly has some delay built in, and the effects of a lot of the cost reductions we made late last year are only now beginning to show up. Based on actions already taken and further cuts already in progress during the second quarter, we expect to see this improvement speed up over the next several quarters; all told, margin headwinds came from geopolitical tensions affecting fuel prices as well as operational expansion that moved at an aggressive pace exceeding what we had initially anticipated. It is our view that these margin pressures are short-term in nature and do not represent our longer-term profitability profile. Our top line is robust and becoming more so. During the first quarter we hit record volumes across every major business line, as U.S. Medical Transportation rose 17%, health care in the home rose 46%, mobile phlebotomy rose 8%, cardiac and remote patient monitoring rose 13%, and virtual care and lab orders rose 37% year-over-year. Before I turn things over to Norm, I'd also like to touch briefly on the strategic alternatives process that was announced on March 16 of this year. Though I'm clearly constrained in what I'm able to say, the company's evaluation of strategic alternatives is still ongoing. Although no assurance can be given that this process will lead to DocGo pursuing any particular transaction or other strategic outcome, we will share additional developments when appropriate. I'll now pass it to Norm, who will walk through the financial details.
Norman Rosenberg
executiveThanks, Lee, and good afternoon to everyone. For Q1 of 2026, total revenue came in at $75.6 million, versus $96 million during the same quarter in 2025. That drop in revenue compared with a year earlier stemmed completely from migrant-related projects winding down. If you set aside those migrant-related revenues, our revenue rose 24% compared with a year earlier in Q1. Part of that gain came from the recent SteadyMD acquisition, which contributed $9.5 million of revenues during Q1 of this year. If you set aside both the migrant-related revenues from the 2025 period and the SteadyMD revenues from the 2026 period, revenues were still up roughly 8% compared with a year earlier. Medical transportation services revenue climbed to $51.9 million in Q1 of 2026, up from the $50.8 million in transport revenues we posted during 2025's first quarter, and that marked the highest quarterly transport revenues ever for DocGo. Those revenues got pushed higher by improvements in both large and small U.S. markets, with some of the strongest growth coming in markets such as New York, Texas and Tennessee; across most of our markets, we keep seeing demand rise. Mobile Health revenue in 2026's first quarter totaled $23.6 million, a decline from $45.2 million during last year's first quarter, again because migrant revenues wound down. Non-migrant mobile health revenues more than doubled, helped by growth in care gap closures, remote patient monitoring and mobile phlebotomy, along with the addition of revenues from SteadyMD, which we acquired during 2025's fourth quarter. If you set aside SteadyMD's impact, Mobile Health revenues were still up roughly 38% compared with a year earlier. Adjusted EBITDA for Q1 of 2026 was negative $10.2 million, against an adjusted EBITDA of negative $3.9 million during 2025's first quarter. Adjusted gross margin — which takes out depreciation and amortization's impact and is the margin measure we watch most closely — came to 31.6% in 2026's first quarter, versus 32.1% in 2025's first quarter. Still, if you look only at revenues from business lines active in both periods — thus taking out Migrant revenues of $35 million and gross profits of $12.3 million from 2025's first quarter, and taking out SteadyMD revenues of $9.5 million and gross profits of $2.8 million from 2026's first quarter — adjusted gross margins for the underlying business would have been 31.9% in Q1 of 2026, an increase of about 1.5 points from 30.4% during last year's first quarter. In 2026's first quarter, adjusted gross margins for the Medical Transportation segment reached 31.9%, versus 30.8% in Q1 of 2025. Medical Transportation gross margins remain held back by effective hourly wages for field labor that came in above plan. Even so, we made solid progress toward growing our field headcount during 2026's first quarter, and during 2026's first quarter we saw the overtime rate fall, getting closer to the sub-10% overtime rates recorded in 2024's first half. Fuel expenses, which rose, played a part in dragging down transport gross margins too, as Lee mentioned before. For the Mobile Health segment, adjusted gross margin landed at 31%, compared with 30.8% during 2025's first quarter. At SteadyMD, gross margins ran a number of points beneath the usual level, a reflection of the aggressive hiring done in the first quarter to catch up with rising demand from large customers. That factor — which should reverse beginning in Q2 — was offset by bigger relative contributions from higher-margin service lines inside mobile health, including remote patient monitoring and mobile phlebotomy. Revenue beat expectations by a wide margin and gross margins were broadly in line, yet operating expenses ran above what we had anticipated; the reason is the need to ramp up hiring, onboarding and training of mobile health clinical staff to satisfy customer demand, plus the fact that our cost-cutting decisions around vendor spending and corporate headcount, made in late Q4 and into 2026, won't meaningfully hit our income statement until the second quarter; with SteadyMD's recent hiring push now behind us, our ongoing cost-cutting efforts in Q1 and additional savings from the efficiency portfolio initiative we discussed on last quarter's call — anticipated to positively impact our second half 2026 results — we still expect sequential declines in SG&A in dollar terms as the year progresses. At March 31, 2026, total cash and cash equivalents, including restricted cash and investments, stood at $59.9 million, a decrease from $68.3 million at the close of 2025. Our quarter-end cash balance came in below what we had anticipated, owing to a delay in collecting migrant-related accounts receivable owed by New York City's Department of Housing Preservation and Development, which we had thought would arrive during the first quarter. Even so, on April 1, the opening day of the second quarter, we collected roughly $8 million of these receivables, and we are working to collect what remains of them. With some additional, though smaller, operating losses in Q2 of 2026 and several growth-related initiatives that require working capital, we would anticipate cash declining further in the near term. That could produce some working capital pressure, which should ease in the second half of the year, consistent with our planned return to profitability. Turning to 2026 for the rest of 2026. As Lee said in his earlier comments, and as we noted in our press release, we have updated and raised our revenue guidance for the year, based on what we have observed in the first 4-plus months of the year and the positive volume trends across most of our business lines. We now project full year revenues in the range of $310 million to $315 million, up from the range of $290 million to $300 million that we shared in mid-March and above our initial guidance of $280 million to $300 million. This figure excludes any revenue coming from projects connected to migrants, and compared with the base revenues for 2025, it would mean growth of 19% to 25%. Our expectation for the full year remains an adjusted EBITDA loss between $5 million and $10 million, the same as what we guided previously. With that, I want to hand the call back to the operator so we can move into the question-and-answer portion. Operator, go ahead.
Matt Shea
analystOperator: Matt Shea here, filling in for Ryan. Let's begin with SteadyMD. It's good to see the momentum carrying over from the prior quarter, particularly given that new win. Lee, could you go a bit deeper on that segment? What does the pipeline look like for new logos compared with expansion among existing ones? And is the bulk of this demand coming from online pharmacies focused on weight loss, or are there other customer categories we should mention? Then, Norm, regarding the top line guidance, it appears most of it came from SteadyMD's weight loss customers, but I'd be curious whether you can add any further detail.
Lee Bienstock
executiveOf course. Matt, good to hear from you. I really appreciate that question. On the piece about growth and what we're seeing in the SteadyMD pipeline, as I said in our prepared remarks, we're very encouraged and excited about the growth prospects there. I believe that growth is arriving from both directions — our current customer base. We keep expanding our capacity and increasing our volumes with the existing customers we've now been serving for quite a while. And we've been bringing on new logos fairly steadily through the latter part of last year and into this year, which is driving additional growth too. And the major push we undertook in Q1 of this year was to accelerate hiring so we could match this growth and satisfy the demand. As for the kinds of customers we serve, we're really working with — you brought it up — the online pharmacies. I mentioned one we're rapidly expanding with. Digital health companies, wellness companies, and digital wearable companies are all partnering with us, along with the typical labs you'd expect too. So we're truly seeing growth throughout that space. Yes, it's weight loss, but it's also the general wellness trend, plus the consumerization of health care, that's really driving growth for us there; so we're very, very excited about it. The SteadyMD team is a great, great team, a great addition. And as we move through this year, some of the growth will also come from DocGo's in-home visits. We really want to drive SteadyMD's telehealth capacity to be a key component of overseeing prescribing, treatment planning, and the visits happening in the home with our mobile health clinicians. That's a big, big area of integration for us as we go through the year here, and it will help us also expand our margins for those in-home visits; so we're really seeing it across the board, a really great addition to the team, and it fits nicely into the future of health care, care anywhere vision we're pursuing, and we couldn't be more excited. Norm?
Norman Rosenberg
executiveMatt, regarding the top line, I believe you mean the guidance we provided, where we're moving to a range of $300 million to $315 million — so a midpoint of $307.5 million — versus the prior range of $290 million to $300 million. Taking a $295 million midpoint there, we're basically raising guidance by $12 million. You can view this a few different ways. First, looking at our Q1 quarterly results, the figure we posted — roughly $75.5 million, $75.6 million — is likely around $3 million to $4 million better than our expectation. That's a solid start. But breaking it out across the business entities, of that roughly $12 million top-line midpoint-to-midpoint guidance increase, I'd attribute about $8 million to $9 million to SteadyMD. Our projection for it was necessarily somewhat conservative — we'd only owned the company for roughly a month or 2 when we issued that prior guidance — and it has pleasantly surprised us on volumes, with the volume growth Lee mentioned. Still, that's just one piece. Transport is doing very well. We had a thesis discussed a couple of times on this call: we knew demand existed, we examined how many calls and trips we couldn't serve due to insufficient personnel, and we knew adding headcount — adding field labor — would convert into more volume. That has worked. So far, that piece is clearly working. Viewed that way, it certainly contributes to growth too, or at minimum confirms the transport growth we anticipated. Then there are some smaller mobile health lines, such as the mobile phlebotomy business and the CRMS business, the remote patient monitoring business, which grew around 20% year-over-year in Q1. So again, most of the increase ties to SteadyMD, but we're seeing solid volume growth, as Lee said in his prepared comments, really across all our business lines.
Matt Shea
analystAll right, that's fantastic detail. I'm grateful for that from each of you. Then perhaps we could shift to a different topic that came across as quite robust this quarter — once more, regarding the payer side along with the care gap closure operation. It's good to watch the number of lives in that area move past what you might describe as the 1.5 million threshold. Perhaps to start, it has been a highly dynamic stretch for the payers. Is there anything different in the way they're aiming to engage you for these care gap closures, or in the services they'd like you to put greater emphasis on compared with what got emphasis previously? Then secondly, I believe back earlier in this year at our conference, you discussed something like a pipeline consisting of 2 to 4 additional payers that you might bring aboard during the first half of this year. I couldn't tell from your prepared remarks whether you'd added 1 or 2 during this quarter, so perhaps you could bring us up to date on your thinking there — whether that remains the correct frame for the additional payers you're signing in the first half, and possibly where things stand on that thus far?
Lee Bienstock
executiveCertainly. I'm pleased you raised that point. Regarding what the payers want from us, I'd say it aligns closely with what we've observed while developing this offering across really the past 18 to 24 months — namely, without question, the care gap service, closing care gaps, especially for patients who slip through the cracks, who are drifting or unattached. That remains a substantial market need, with truly no shift on that front, and we've been increasing our capability and expanding — genuinely expanding our volumes compared with a year earlier as we continue developing that line of business. I think the other element we're truly noticing is that when we go see the care gap — the patients with open care gaps — we find many of them are likewise unattached or unaware of who their primary care provider is, and a very substantial share, most of whom lack a PCP, are choosing to have us serve as their PCP. So those are the services we're genuinely layering on top of the care gap closure offerings, and we've kept doing so. During the first quarter, it was rather striking that when we visit patients at home for care gap as well as for PCP services, we observe that 60% of the patients we visit have 2 or more chronic conditions; and a large share of them have 3 or more chronic conditions. 20% of them have social needs or risks affecting their health outcomes. We also observe that 42% of the patients had chronic conditions that had never previously been documented. So these are significant drivers for the health plans, and we're capable of uncovering this, capable of meeting patients where they are. And that ties in with the readmission cut of more than 50% we are observing among the longitudinal care patients we have been serving. Therefore, the effect on health outcomes is genuinely significant. Beyond the care gap services, we are beginning to deliver a greater amount of longitudinal care. Plus, finding chronic conditions that previously went unrecorded is an enormous advantage for the health plan and, naturally, for the patient. That is genuinely what the plans rely on us for. That is the data and the insight we send back to them, and it is turning out to be extremely valuable. Naturally, we believe we will succeed and keep expanding the company as we deliver ever more value. Most of the plans we partner with have informed us they want to grow with us during the next year. So once more, that has given us plenty of excitement, optimism, and enthusiasm about what we are doing in that area. Regarding the new logos, I realize you brought that up, Matt — about the new logos, we will announce them when it makes sense, yet we are definitely on track to bring on 2 to 4 new logos during the first half of this year.
Kieran Ryan
analystKieran Ryan here, filling in for Pito. Thanks for all the detail you provided. I suppose, taking a step back, maybe you could help us get a handle on the puts and takes regarding why the EBITDA guidance was reaffirmed — specifically how the favorable factors from the very strong revenue beat and with SteadyMD might be counterbalanced by added unfavorable factors on the labor cost and transportation side and with SteadyMD, plus on the fuel side. How should we view all of that netting out to the reaffirmed range?
Norman Rosenberg
executiveYou sort of answered it yourself there, Kieran. What's going on is we believe we've got some genuinely solid momentum when it comes to revenue, which is shown by the fact that we beat our figure for Q1 and we lifted the full-year guidance. And the explanation for keeping the total EBITDA guidance unchanged despite a higher revenue expectation comes down to those items you brought up, correct? There's going to be a bit of strain on gross margins in the transport segment during Q2 stemming from fuel prices. Lee noted that our average gas price came in at roughly $3.69 per gallon in March, which was up from $2.93 in January and February; right now that figure is around $4. We don't expect that to persist much past the second quarter, but it's something we need to factor in. Admittedly, we aren't as exposed to fuel prices as perhaps we once were back when we were purely an ambulance company; even so, it will still make a difference and might cost us somewhere between 1/3 of a point and 0.5 point in gross margin, which clearly will affect — will cancel out part of the benefit we'd get from margins coming in above what we'd initially planned; regarding operating expenses, a portion of what Lee brought up ties to SteadyMD. I did mention in my remarks that our — there's been a delay in our cost reductions or in how that ultimately shows up on our income statement; so we anticipate capturing some upside there in Q2, though we're beginning from a slightly elevated level. So we simply want to incorporate a bit of caution on that front too, in case operating expenses keep running somewhat hotter than what we had anticipated.
Kieran Ryan
analystGot it, that helps. Now, I think you said that after accounting for SteadyMD and the migrant revenue in 1Q '25, mobile health's growth was 38% for that quarter. And I see you're grouping some business lines under Health Care at Any Address, which appears to hold the bulk of the dollars in mobile health. Could you give us a better picture of which business lines are driving the biggest growth in dollar terms excluding SteadyMD? There are obviously some very high percentage growth rates across the board, but we'd like to understand that more clearly.
Lee Bienstock
executiveYes. When you look at it in terms of dollars, what I'd say is that our patient monitoring unit is putting up very impressive year-over-year gains, and it pairs that expansion with a very robust margin picture. On top of that, you've got the health care in the home segment growing, our care gap in primary care continues to widen compared with last year, and our mobile phlebotomy service is also expanding. Those make up the 3 components. And of course, there's SteadyMD, which you mentioned. Those are the areas experiencing the quickest growth. We're seeing these pieces start to connect with each other. SteadyMD is supervising the in-home visits that DocGo performs, bringing in phlebotomists for those care gap appointments at people's homes, and using patient monitoring where it's appropriate for individuals we see at their residences. So with that care at any address, health care anywhere portfolio, watching it expand is something we're genuinely thrilled about, and having one component play a role and support the other reflects the vision we hold as we deliver care through virtual, in-person, and remote means. That particular area is currently the fastest-growing part of our business.
Richard Close
analystSure. Perhaps I'll just piggyback on what was asked most recently, plus a few things raised before that. Starting with SteadyMD, though — I believe when we wrapped up the fourth quarter, you described it as roughly a $25 million to $30 million operation, let's say, for 2026. So given what was said about the guidance, would something like $34 million to $39 million now be a fair figure for SteadyMD in '26? Let's begin there.
Lee Bienstock
executiveAbsolutely. Thanks for that, Richard. So, to build on what Norm said, SteadyMD generated roughly $9.5 million during Q1; we generally find that Q1 and Q4 represent the peak periods for SteadyMD, since those winter months come as one year wraps up and the next begins; yet, as you point out, that $9.5 million essentially translates to a $36 million annualized pace, though we recognize that volume typically dips somewhat during the middle portion of the year. That said, we're adding more customers. We're bringing additional customers onboard, which could help even things out over the course of the year; but fundamentally, as you noted, that's the rate they're moving at once Q1 ends.
Richard Close
analystAll right, and just so I understand clearly, regarding that $23.6 million figure for mobile health, you've got the $9.5 million tied to SteadyMD. There is basically zero migrant in any of those figures, or in mobile health for the quarter. It's entirely absent now, right?
Norman Rosenberg
executiveRight.
Richard Close
analystAll right, and perhaps returning to what was asked just before mine — so when we consider remote monitoring, and we take out mobile SteadyMD from the $23.6 million total for mobile, would remote monitoring be the largest portion of whatever else is left in there?
Norman Rosenberg
executiveIt is the largest — Richard, among the individual pieces it ranks first; it came in slightly above $4 million, I would put it at $4.1 million for the quarter. But just so you have a sense, the clinical staffing business was roughly $3.8 million, $3.7 million, $3.8 million. So that was a near second. Still, yes, it genuinely is the largest one, running at a margin of more than 60% for the quarter. The natural margin is likely somewhat under that, yet it is comfortably above 50%. So that truly benefits the overall margin picture for Mobile Health.
Richard Close
analystAll right. We've got a lot of terminology flying around in this conversation, but when you say clinical staffing, that refers to care gap closure and PCP, right?
Lee Bienstock
executiveYes, so clinical staffing is essentially the part of our operations where we provide support for mobile clinics as well as clinical staffing on behalf of our health care partners. In other words, these are programs we operate for clinical groups — for instance, we work with radiology groups and similar organizations, running staffed clinics for them.
Norman Rosenberg
executiveThis is a legacy government medical services business that we acquired, if I recall correctly, back in 2022.
Richard Close
analystAll right. So remote monitoring comes in at $4.1 million, staffing sits at $3.8 million, and after that we'd have care gap closure, or the home, health care in the home, followed by mobile phlebotomy.
Lee Bienstock
executiveThat's right. Yes; and with health care in the home, we — once more, mobile phlebotomy is among the service offerings we provide in the home, correct? So primary care, care gap closure, mobile phlebotomy. In those situations, a clinician is being sent by us into the home. That's essentially the care in the home service line; the reason we're calling out mobile phlebotomy is that it's among the fastest-growing pieces of that care in the home business.
Richard Close
analystSo that's significant expansion, much of it building on a fairly small base, yet the forward movement keeps going. Turning to fuel costs, when you mention anticipating some easing there — perhaps specifically on the transport side — what share is represented by the fixed rate programs compared with the lease rate programs? What direction is that mix heading? Also, under those agreements, does any fuel relief come your way? Or what's the right way to think about it?
Norman Rosenberg
executiveYou mean the leased-hour arrangements?
Richard Close
analystYes.
Norman Rosenberg
executiveNo, nothing of that sort has been incorporated, in my view. What I mean is, this has been a topic of discussion among us during these past few weeks. Broadly speaking, be it regarding staffing levels or regarding fuel, we genuinely have to revisit certain agreements we hold and attempt to incorporate some form of automatic adjustment tied to indexed costs, yet such a provision is absent from the overwhelming majority of those agreements. The way this manifests is that when we consider lease hours as opposed to fee-for-service, we tend to evaluate the situation and conclude that fewer trips is preferable, since that means less fuel being consumed. Beyond that, however, this isn't truly something within our ability to manage.
Richard Close
analystOkay. Okay. So about those cost cuts — they start kicking in during Q2. When would we actually see the full, the full benefit from them? Is that somewhere in the middle of Q3, or does it really show up in Q2 itself?
Norman Rosenberg
executiveI'd say the full benefit probably hits at some point in Q3; and I say that keeping in mind the kind of vendor list we have in place for those very specific cost-cutting moves. Richard, part of the reason our expenses ran higher than we'd expected in — than what we'd initially forecast for Q1 is that typically, what happens is we swap one vendor for another one. A cheaper one, or we just stop working with a vendor altogether. But here, it's the kind of case where you've got a list of vendors and you've got those savings identified and executed, but there's a lag because I might be locked into a contract with that vendor through the end of March, even though I told them in January they're no longer needed or told them back in December they're no longer needed; and the same thing holds for some employees. As we work our way further up into the corporate layer here, where we're trying to take out some cost. What ends up happening is we run into situations where someone gets told, hey, look, we've marked this position for elimination, but we need you to stick around another 30 days or 60 days. That basically pushes you into the next quarter. And that's why it ends up happening. So based on what we've done so far in Q2, and based on what's scheduled to be done between now and when Q2 ends, I'd say we won't get the full benefit of every one of those items this quarter. But once Q3 comes, we should get almost all of it. Of course, in Q4, we'll have whatever happened at the end of Q2 and Q3 flowing through the P&L. So assuming things go the way we expect and nothing else comes up that would cause us to add headcount or bring on more vendors we don't currently use, we'd expect that quarter-over-quarter decline in operating expenses as we head into Q2, 3 and 4. That said, we are looking at roughly 10.6 as well.
Richard Close
analystAlright. And nice work on the collections there. I believe you mentioned something like $8 million as of April 1.
Norman Rosenberg
executiveThat's right. <<inaudible>> mix.
Richard Close
analystAll right. What amount remains unpaid, and how are you thinking about the timing for receiving it?
Norman Rosenberg
executiveYeah. Regarding HPD — the agency we referenced, Housing Preservation and Development — roughly $13 million is still owed, I believe. We're currently in touch with them, resending, in certain instances, the identical details we provided previously, and in other instances, transmitting it through a different channel. There's a formal procedure we'd follow for that. They've now specified for us precisely what is deemed "missing" before we can be compensated for those items; we're compiling those details and forwarding them. I'd say — well, when I check their payment system, my estimate is that roughly another $1 million will arrive, perhaps within the coming couple of weeks. Past that, we'd anticipate receiving it across the remainder of 2026. Something we've discovered, despite having already gathered 97% of that contract's value, is that forecasting the precise schedule for those payments is extremely, extremely challenging. Consequently, we aim to lean toward caution. On the flip side, speaking of migrant revenues, there's HPD, but also New York City Health and Hospitals, plus the HERC program we mentioned — every bit of that has been gathered, and it came in quite promptly regarding what we invoiced as those programs wrapped up in late 2025. Thus, nothing material remains unpaid on any of those contracts at this moment, as far as I can tell; it all came through during Q1. So essentially that roughly $13 million is what's still lingering out there, and we're striving extremely, extremely diligently to gather it.
Jenny Shen
analystThis is Jenny Shen, filling in for Dave. I was hoping to get some additional detail on SteadyMD's weight management business, or program. In the prepared remarks, I believe you brought up a new contract or partnership with an online pharmacy. Could you expand on that a bit? Is the pharmacy you're working with one that provides the branded medications? Or do they supply the compounds? And what does the revenue sharing structure look like?
Lee Bienstock
executiveSure. Regarding revenue, we bill a per visit rate. Revenue sharing isn't involved; we simply charge our contracted rate, as you pointed out, Jenny. As for the part of your question about weight loss medication, we're dealing with the branded weight loss medications, the pharmacies providing those branded weight loss options, and we handle the clinical visit as part of that prescription, as part of that prescribing process; so that's really what's fueling the growth there. Naturally, we're seeing, clearly, in the marketplace, a significant tailwind and growth in that area, and we are taking part in that.
Jenny Shen
analystAll right, that's great. Could you also refresh our memory on what portion of total revenue the payer side is anticipated to bring in during 2026? And what figure do you have in mind for SteadyMD?
Lee Bienstock
executiveSure thing. As we stated, our outlook was revised to a range of $300 million to $315 million for this year. And, as we also discussed during the prior earnings call, we're looking at roughly $85 million to $100 million originating from the Mobile Health segment, with approximately $210 million to $215 million generated by the Medical Transportation segment across the rest of the year. Regarding SteadyMD, which I believe Richard specifically inquired about, as was noted, SteadyMD closed out Q1 with a $9.5 million quarter. So across the year, per our projections, they're delivering somewhere around $35 million to $36 million.
Lee Bienstock
executiveThanks a lot. I appreciate all of you being here, and I can't wait to talk with you once more before long. Enjoy the rest of your night.
Operator
operatorThanks. That wraps up the conference call for today, everyone. Appreciate all of you being here. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.